HOUSTON--(BUSINESS WIRE)--Edgeline Holdings, Inc. (OTCBB:ELHI), which recently announced a name change to Oncolin Therapeutics, Inc., announced that Dr. Sandra Silberman has agreed to join the Scientific Advisory Board. Dr. Silberman is a world renowned oncologist who has been involved in both cancer research and the development of important new cancer therapeutics. At Pfizer, she pioneered the early clinical development of Tarceva and went on to be clinical director of the Gleevec program at Novartis. She continues to be involved in the development of novel cancer therapies being developed by Industry.
